Abbott Laboratories (ABT)vsHyperfine Inc (HYPR)
ABT
Abbott Laboratories
$104.83
+0.74%
HEALTHCARE · Cap: $180.82B
HYPR
Hyperfine Inc
$1.15
-4.96%
HEALTHCARE · Cap: $120.49M
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 326730% more annual revenue ($44.33B vs $13.56M). ABT leads profitability with a 14.7% profit margin vs -2.6%. ABT earns a higher WallStSmart Score of 51/100 (C-).
ABT
Buy51
out of 100
Grade: C-
HYPR
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-315.5%
Fair Value
$25.23
Current Price
$104.83
$79.60 premium
Intrinsic value data unavailable for HYPR.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Strong operational efficiency at 21.6%
Generating 2.6B in free cash flow
Revenue surging 128.0% year-over-year
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.4% revenue growth
Weak financial health signals
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -79.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : HYPR
The strongest argument for HYPR centers on Revenue Growth, Price/Book. Revenue growth of 128.0% demonstrates continued momentum.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : HYPR
The primary concerns for HYPR are EPS Growth, Market Cap, Piotroski F-Score.
Key Dynamics to Monitor
ABT profiles as a value stock while HYPR is a hypergrowth play — different risk/reward profiles.
HYPR carries more volatility with a beta of 1.11 — expect wider price swings.
HYPR is growing revenue faster at 128.0% — sustainability is the question.
ABT generates stronger free cash flow (2.6B), providing more financial flexibility.
Bottom Line
ABT scores higher overall (51/100 vs 25/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Hyperfine Inc
HEALTHCARE · MEDICAL DEVICES · USA
Hyperfine Inc. is a pioneer in medical technology, focusing on transforming access to MRI with innovative point-of-care imaging solutions. As the developer of the first FDA-cleared portable MRI system, the company significantly enhances patient care by delivering high-quality imaging directly at the bedside, which streamlines clinical decision-making. By emphasizing cost efficiency and patient convenience, Hyperfine is strategically positioned to capitalize on the escalating demand for advanced diagnostic imaging solutions in a rapidly changing healthcare environment. Its groundbreaking technology is poised to make a substantial impact on healthcare delivery across various medical settings, representing a promising opportunity for institutional investors.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?